+0.04 (+4.12%)
Dilution Risk
Revenue
16.00 K
R&D Expenses
5.28 M
Operating CF
-7.48 M
Total Assets
38.24 M
Total Liabilities
35.68 M
Equity
2.56 M
D/E Ratio
12,345
Cash Position
18.75 M
Monthly Burn
2.49 M
Runway
6.6 mo
Burn Trend
SEC Filing
May 14, 2026locked
| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SENTI-202 Monoclonal antibody | AML/MDS | Phase 1 | NCT06325748 | 26% | $106M | ACTIVE NOT_RECRUITING | 21 | SLOW | D (27) | Aug 1, 2040 | MODERATE_RISK | LOW May 26, 2026 |
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
SENTI-202 | Acute Myeloid Leukemia,relapsed/refractory hematologic malignancies | Phase 1 | 2025-06-19 | |||
SENTI-202 | Acute Myeloid Leukemia,relapsed/refractory hematologic malignancies | Phase 1 | 2025-06-19 | |||
SENTI-202 | Acute Myeloid Leukemia,relapsed/refractory hematologic malignancies | Phase 1 | 2025-06-19 |
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Senti Biosciences will present its innovative Logic-Gated cell therapies at the AACR Annual Meeting 2026. CEO Timothy Lu will discuss the advancements of the SENTI-202 therapy, which selectively targets cancer cells while protecting healthy ones. The session aims to highlight the potential of Logic Gates in oncology, particularly for relapsed/refractory acute myeloid leukemia.
Read more →Senti Biosciences has published new research in Cell Systems showcasing its innovative NOT-gated CAR circuits, which enhance the precision and safety of cell therapies. The study indicates that these circuits can improve the efficacy of immune cells in targeting tumors while sparing healthy tissue. This research supports Senti's ongoing development of its Gene Circuit platform for cancer treatments.
Read more →Senti Biosciences reported its financial results for Q4 and full year 2025, highlighting significant progress in its clinical pipeline, particularly with SENTI-202 for relapsed/refractory AML. The company received RMAT designation from the FDA and reported positive preliminary clinical data. However, it also faced a substantial net loss for the year.
Read more →Senti Biosciences is set to present clinical and translational data for its SENTI-202 program at the 11th Annual Innate Killer Conference. The Phase I trial focuses on a novel CAR NK cell therapy targeting CD33 and FLT3 in adults with relapsed/refractory acute myeloid leukemia. Presentations will highlight both clinical results and the therapy's unique mechanism of action.
Read more →Senti Biosciences, a clinical-stage biotechnology company, announced that CEO Timothy Lu will present at the Leerink Partners 2026 Global Healthcare Conference in Miami on March 9, 2026. The company focuses on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, which aims to enhance precision in targeting cancer cells. A webcast of the presentation will be available on their website.
Read more →Senti Biosciences, a clinical-stage biotech firm, will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026. CEO Timothy Lu will discuss the company's Gene Circuit technology, pipeline advancements, and partnership opportunities. The event will be available via live webcast, emphasizing Senti's commitment to developing innovative therapies for incurable diseases.
Read more →Senti Biosciences participated in the Cell & Gene Live event, discussing advancements in cell therapy development. The company highlighted its Gene Circuit platform and its product candidate, SENTI-202, designed to target hematologic malignancies. SENTI-202 has received FDA designations for its potential in treating relapsed/refractory conditions. The event facilitated valuable industry discussions on innovative therapeutic solutions.
Read more →Senti Biosciences has completed enrollment in its Phase 1 clinical trial for SENTI-202, a CAR NK cell therapy targeting relapsed or refractory acute myeloid leukemia (R/R AML). The trial showed promising results, including durable complete remissions and a favorable safety profile. The company plans to discuss the next steps with the FDA in 2026, aiming for a pivotal study and potential expansion into newly diagnosed and pediatric AML.
Read more →Senti Biosciences has been selected to present at the Healthcare Conference Taipei 2026, where CEO Timothy Lu will discuss the company's Gene Circuit technology. The presentation aims to highlight the company's progress and potential partnerships in cell and gene therapies. The event is expected to attract global investors and strategic partners.
Read more →Senti Biosciences participated in a Virtual Investor CEO Connect Segment, where CEO Timothy Lu discussed the FDA's granting of RMAT designation to SENTI-202, a CAR-NK cell therapy. This investigational therapy is aimed at treating relapsed/refractory AML and builds on previous Orphan Drug Designation. Recent clinical trial data from 20 patients was also shared at the ASH Annual Meeting.
Read more →Senti Biosciences, Inc. will participate in the Biotech Showcase 2026, with CEO Dr. Timothy Lu as a panelist. The panel will focus on advancements in cell and gene therapies. The event, scheduled for January 12-14, 2026, in San Francisco, serves as a key networking platform for biotech companies and investors.
Read more →Senti Biosciences has received FDA Regenerative Medicine Advanced Therapy designation for its investigational cell therapy, SENTI-202, aimed at treating relapsed or refractory acute myeloid leukemia (AML). This designation underscores the urgent need for improved therapies in this area and highlights SENTI-202's potential to transform treatment outcomes. The therapy has shown promising clinical results, as presented at the recent ASH Annual Meeting.
Read more →Senti Bio has announced promising results from its ongoing Phase 1 trial of SENTI-202, a CAR NK cell therapy for relapsed or refractory Acute Myeloid Leukemia (R/R AML). The data presented at the ASH Annual Meeting highlights deep, durable complete remissions and a favorable safety profile. The therapy has received RMAT designation from the FDA, validating its potential to address unmet medical needs in AML treatment.
Read more →Senti Bio will host a conference call on December 9, 2025, to discuss updated clinical results for SENTI-202, a CAR-NK cell therapy targeting hematologic malignancies. The call will feature key executives and a hematologist involved in the study. SENTI-202 aims to selectively eliminate cancer cells while protecting healthy bone marrow.
Read more →Senti Biosciences reported its third quarter 2025 financial results and announced plans to present clinical data from its Phase 1 SENTI-202 study at the upcoming ASH Annual Meeting. The data will focus on patients with relapsed/refractory acute myeloid leukemia (AML) and aims to demonstrate the efficacy and safety of their Gene Circuit technology. The company is actively expanding patient enrollment and achieving significant milestones in its clinical development.
Read more →Senti Bio announced it will present updated clinical results for its SENTI-202 therapy at the ASH Annual Meeting in December 2025. This first-in-class cell therapy targets CD33 and FLT3 in relapsed/refractory acute myeloid leukemia (AML) while protecting healthy cells. The company aims to address the significant unmet need for effective AML treatments.
Read more →Senti Biosciences, Inc. announced that CEO Timothy Lu will present at Chardan's 9th Annual Genetic Medicines Conference on October 21, 2025, in New York. The company is focused on developing next-generation cell and gene therapies using its Gene Circuit platform. Management will also hold one-on-one meetings with investors during the event.
Read more →Senti Biosciences, Inc. will present at BioJapan from October 8-10, 2025, in Yokohama, Japan. CEO Timothy Lu will deliver a presentation on October 9, focusing on the company's Gene Circuit platform for cell and gene therapies. Senti Bio will also engage with investors through one-on-one meetings and has a booth at the event.
Read more →Senti Biosciences, Inc. announced that Dr. Kanya Rajangam will present at the MedInvest Biotech & Pharma Conference on September 24, 2025. The presentation will focus on their proprietary Gene Circuit platform, which is aimed at developing advanced cell and gene therapies. Additionally, management will hold one-on-one meetings with investors during the conference.
Read more →Senti Biosciences, Inc. will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025. CEO Timothy Lu will discuss the company's advancements in cell and gene therapies using their Gene Circuit platform. The event will also include opportunities for in-person meetings with investors. A live video webcast of the presentation will be available.
Read more →Senti Biosciences, a clinical-stage biotech firm, will present at the Webull Financial Corporate Connect Webinar Series from August 19-21, 2025. CEO Timothy Lu will lead the presentation on their innovative Gene Circuit platform, which aims to develop advanced cell and gene therapies. This event highlights Senti Bio's commitment to addressing incurable diseases.
Read more →Senti Bio participated in a virtual investor segment discussing its Phase 2 dose selection for SENTI-202, a CAR-NK cell therapy targeting acute myeloid leukemia. Dr. Kanya Rajangam highlighted the therapy's potential as a first-in-class treatment for relapsed/refractory hematologic malignancies. The segment reflects Senti Bio's commitment to developing advanced therapies using its Gene Circuit platform.
Read more →Senti Biosciences reported its Q2 2025 financial results and highlighted advancements in its Phase 1 SENTI-202 study for Acute Myeloid Leukemia (AML). The company has completed dose finding and confirmed the recommended Phase 2 dose, now entering the dose expansion phase. Additionally, Senti Bio received Orphan Drug Designation for SENTI-202 and anticipates releasing more data by the end of the year.
Read more →Senti Biosciences has established the recommended Phase 2 dose (RP2D) for its investigational therapy SENTI-202 in a Phase 1 study targeting relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML). The RP2D is set at 1.5 x 10^9 CAR+ NK cells administered in a specific schedule. Preliminary results indicate a favorable safety profile and significant remission rates among patients. The company plans to release further clinical data by year-end.
Read more →Senti Biosciences participated in the Virtual Investor 'What’s Your Story' Summer Spotlight On-Demand Conference, where CEO Timothy Lu discussed his commitment to the company and its innovative programs. The on-demand video is available for viewing on the company's website and virtual investor platform. Senti Bio focuses on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform.
Read more →